-
Je něco špatně v tomto záznamu ?
Coronary Artery Spasm During Pulsed Field vs Radiofrequency Catheter Ablation of the Mitral Isthmus
C. Zhang, P. Neuzil, J. Petru, M. Funasako, P. Hala, K. Kopriva, JS. Koruth, SR. Dukkipati, VY. Reddy
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, komentáře
- MeSH
- dospělí MeSH
- fibrilace síní * chirurgie patofyziologie MeSH
- katetrizační ablace * škodlivé účinky MeSH
- koronární vazospasmus * etiologie MeSH
- lidé MeSH
- nitroglycerin MeSH
- prospektivní studie MeSH
- senioři MeSH
- srdeční síně patofyziologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- komentáře MeSH
IMPORTANCE: In treating atrial fibrillation, pulsed field ablation (PFA) is a novel energy modality with comparable efficacy to conventional thermal ablation, such as radiofrequency ablation (RFA), but with the benefit of some preferentiality to myocardial tissue ablation. Studies have demonstrated important safety advantages, including the absence of esophageal injury or pulmonary vein stenosis and only rare phrenic nerve injury. However, there is emerging evidence of coronary artery vasospasm provoked by PFA. OBJECTIVE: To compare the incidence and severity of left circumflex arterial vasospasm between PFA and RFA during adjacent ablation along the mitral isthmus. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study enrolled consecutive adult patients receiving first-ever PFA or RFA of the mitral isthmus during catheter ablation of atrial fibrillation in 2022 with acute follow-up at a single referral European center. EXPOSURE: A posterolateral mitral isthmus line was created using either a multielectrode pentaspline PFA catheter (endocardial ablation) or a saline-irrigated RFA catheter. Simultaneous diagnostic coronary angiography was performed before, during, and after catheter ablation. Nitroglycerin was planned for spasm persisting beyond 20 minutes or for significant electrocardiographic changes. MAIN OUTCOMES AND MEASURES: The frequency and severity of left circumflex arterial vasospasm was assessed and monitored, as were time to remission and any need for nitroglycerin administration. RESULTS: Of 26 included patients, 19 (73%) were male, and the mean (SD) age was 65.5 (9.3) years. Patients underwent either PFA (n = 17) or RFA (n = 9) along the mitral isthmus. Coronary spasm was observed in 7 of 17 patients (41.2%) undergoing PFA: in 7 of 9 (77.8%) when the mitral isthmus ablation line was situated superiorly and in 0 of 8 when situated inferiorly. Conversely, coronary spasm did not occur in any of the 9 patients undergoing RFA. Of 5 patients in whom crossover PFA was performed after RFA failed to achieve conduction block, coronary spasm occurred in 3 (60%). Most instances of spasm (9 of 10 [90%]) were subclinical, with 2 (20%) requiring nitroglycerin administration. The median (range) time to resolution of spasm was 5 (5-25) minutes. CONCLUSION AND RELEVANCE: When creating a mitral isthmus ablation line during catheter ablation of atrial fibrillation, adjacent left circumflex arterial vasospasm frequently occurred with PFA and not RFA but was typically subclinical.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007773
- 003
- CZ-PrNML
- 005
- 20240423160240.0
- 007
- ta
- 008
- 240412s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1001/jamacardio.2023.4405 $2 doi
- 035 __
- $a (PubMed)38019505
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Zhang, Chi $u Icahn School of Medicine at Mount Sinai, New York, New York
- 245 10
- $a Coronary Artery Spasm During Pulsed Field vs Radiofrequency Catheter Ablation of the Mitral Isthmus / $c C. Zhang, P. Neuzil, J. Petru, M. Funasako, P. Hala, K. Kopriva, JS. Koruth, SR. Dukkipati, VY. Reddy
- 520 9_
- $a IMPORTANCE: In treating atrial fibrillation, pulsed field ablation (PFA) is a novel energy modality with comparable efficacy to conventional thermal ablation, such as radiofrequency ablation (RFA), but with the benefit of some preferentiality to myocardial tissue ablation. Studies have demonstrated important safety advantages, including the absence of esophageal injury or pulmonary vein stenosis and only rare phrenic nerve injury. However, there is emerging evidence of coronary artery vasospasm provoked by PFA. OBJECTIVE: To compare the incidence and severity of left circumflex arterial vasospasm between PFA and RFA during adjacent ablation along the mitral isthmus. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study enrolled consecutive adult patients receiving first-ever PFA or RFA of the mitral isthmus during catheter ablation of atrial fibrillation in 2022 with acute follow-up at a single referral European center. EXPOSURE: A posterolateral mitral isthmus line was created using either a multielectrode pentaspline PFA catheter (endocardial ablation) or a saline-irrigated RFA catheter. Simultaneous diagnostic coronary angiography was performed before, during, and after catheter ablation. Nitroglycerin was planned for spasm persisting beyond 20 minutes or for significant electrocardiographic changes. MAIN OUTCOMES AND MEASURES: The frequency and severity of left circumflex arterial vasospasm was assessed and monitored, as were time to remission and any need for nitroglycerin administration. RESULTS: Of 26 included patients, 19 (73%) were male, and the mean (SD) age was 65.5 (9.3) years. Patients underwent either PFA (n = 17) or RFA (n = 9) along the mitral isthmus. Coronary spasm was observed in 7 of 17 patients (41.2%) undergoing PFA: in 7 of 9 (77.8%) when the mitral isthmus ablation line was situated superiorly and in 0 of 8 when situated inferiorly. Conversely, coronary spasm did not occur in any of the 9 patients undergoing RFA. Of 5 patients in whom crossover PFA was performed after RFA failed to achieve conduction block, coronary spasm occurred in 3 (60%). Most instances of spasm (9 of 10 [90%]) were subclinical, with 2 (20%) requiring nitroglycerin administration. The median (range) time to resolution of spasm was 5 (5-25) minutes. CONCLUSION AND RELEVANCE: When creating a mitral isthmus ablation line during catheter ablation of atrial fibrillation, adjacent left circumflex arterial vasospasm frequently occurred with PFA and not RFA but was typically subclinical.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a fibrilace síní $x chirurgie $x patofyziologie $7 D001281
- 650 12
- $a koronární vazospasmus $x etiologie $7 D003329
- 650 _2
- $a nitroglycerin $7 D005996
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a katetrizační ablace $x škodlivé účinky $7 D017115
- 650 _2
- $a srdeční síně $x patofyziologie $7 D006325
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a komentáře $7 D016420
- 700 1_
- $a Neuzil, Petr $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Petru, Jan $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Funasako, Moritoshi $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Hala, Pavel $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Kopriva, Karel $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Koruth, Jacob S $u Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Dukkipati, Srinivas R $u Icahn School of Medicine at Mount Sinai, New York, New York
- 700 1_
- $a Reddy, Vivek Y $u Icahn School of Medicine at Mount Sinai, New York, New York $u Homolka Hospital, Prague, Czech Republic
- 773 0_
- $w MED00191356 $t JAMA cardiology $x 2380-6591 $g Roč. 9, č. 1 (2024), s. 72-77
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38019505 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423160236 $b ABA008
- 999 __
- $a ok $b bmc $g 2081638 $s 1217540
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 9 $c 1 $d 72-77 $e 20240101 $i 2380-6591 $m JAMA cardiology $n JAMA Cardiol $x MED00191356
- LZP __
- $a Pubmed-20240412